Educational draft · awaiting clinical reviewThe full textbook explains uncertainty but does not replace live national or local guidance, specialist advice, or current prescribing information.
Postmenopausal bleeding and urgent cancer exclusion
Obstetrics and gynaecology · UK scope · Sources checked 27 Aug 2026 · Clinical review pending
!
Stabilise major bleeding before cancer work-up
Haemodynamic compromise, continuous heavy loss, severe anaemia, sepsis or severe pelvic pain requires immediate acute gynaecological care even though the underlying cause still needs malignancy exclusion.
Action: Use ABCDE, obtain urgent bloods and crossmatch, involve senior gynaecology and control bleeding; resume the diagnostic cancer pathway as soon as the patient is stable.
Overview
Treat postmenopausal bleeding as a cancer-exclusion presentation, localise genital and non-genital sources, interpret transvaginal endometrial thresholds in ordinary and HRT contexts, and escalate persistent or recurrent bleeding to histology.
Postmenopausal bleeding is bleeding from the genital tract after 12 months of spontaneous amenorrhoea due to menopause. Clarify whether menopause was spontaneous, surgical or treatment-induced and whether HRT creates scheduled withdrawal bleeding. Ask amount, recurrence, pain, discharge, weight change and source, because haematuria and rectal bleeding are sometimes reported as vaginal. Include anticoagulants, tamoxifen, diabetes, obesity, PCOS history, family cancer history and previous endometrial hyperplasia. Anticoagulation can amplify bleeding but cannot be accepted as the diagnosis.
Cancer exclusion is the organizing priority. NICE NG12 recommends a suspected-cancer pathway referral for unexplained PMB in patients aged 55 and older and advises considering it under 55. Referral should not wait for repeated episodes, anaemia or a primary-care ultrasound. Most PMB is benign, often genitourinary atrophy or a polyp, but prevalence does not identify the individual patient. Explain the need for urgent assessment without saying cancer is inevitable.
Aetiology
01
Atrophic tissue
Low postmenopausal oestrogen thins vaginal and endometrial tissue, making superficial vessels fragile and prone to contact or spontaneous bleeding.
02
Focal benign lesions
Endometrial and cervical polyps create vascular protrusions that can bleed intermittently and may be missed by blind sampling.
03
Hyperplasia and malignancy
Endometrial proliferation, atypia and invasive cancer generate abnormal fragile vessels, particularly with prolonged oestrogen exposure unopposed by progestogen.
04
Hormonal and medicine effects
HRT regimen imbalance, tamoxifen-associated endometrial change and anticoagulants can initiate or amplify bleeding while structural disease may coexist.
Pathophysiology
1
Surface fragility
Atrophic epithelium loses thickness and lubrication, so small vessels rupture with minor friction, inflammation or no obvious trigger.
2
Abnormal endometrial angiogenesis
Hyperplastic and malignant tissue develops disorganised vessels that break down unpredictably, producing spotting, discharge or heavier bleeding.
3
Focal lesion shear
Polyps project into the cavity or cervical canal and undergo intermittent friction, torsion or surface ulceration that produces episodic loss.
4
Exogenous hormone instability
Oestrogen and progestogen dose, adherence and schedule alter endometrial proliferation and shedding, creating regimen-dependent unscheduled bleeding patterns.
Clinical features and red flags
Genitourinary atrophy
Dry pale fragile vaginal tissue, soreness, dyspareunia and contact spotting suggests atrophy, but endometrial disease still requires pathway-appropriate exclusion.
Endometrial polyp
Intermittent spotting with a focal intracavity lesion may represent a polyp and is best assessed and removed hysteroscopically for histology.
Endometrial malignancy pattern
Recurrent bleeding, blood-stained discharge, thick or irregular endometrium, risk factors or uterine enlargement increases concern but early cancer may cause one small spot.
Cervical or vulval source
A visible friable cervical lesion, ulcer, vulval mass or dermatosis localises bleeding outside the endometrium and needs its own urgent diagnostic pathway.
HRT-related bleeding
Timing relative to initiation, dose change and progestogen schedule distinguishes expected adjustment from bleeding needing urgent ultrasound under BMS guidance.
Recurrent thin-endometrium bleedingRed flag
A second episode after an initially reassuring scan can reflect a missed focal lesion and reactivates specialist assessment.
Red flags requiring action
Any genital bleeding more than 12 months after the final spontaneous menstrual period is abnormal and should not be dismissed as a late period.
NICE recommends suspected-cancer referral for unexplained postmenopausal bleeding at age 55 or older and consideration of that pathway below 55.
Investigations
01Urgent referral assessmentFirst step
Why
Apply NICE age and symptom criteria and avoid delay while routine tests are arranged.
Interpretation and limitations
Unexplained PMB at age 55 or older meets suspected-cancer referral; below 55 the same referral should be considered.
02Vulval and speculum examination
Why
Localise atrophy, trauma, cervical polyp, discharge or visible vulval, vaginal and cervical malignancy.
Interpretation and limitations
A benign source may coexist with endometrial disease. Suspicious lesions require targeted urgent referral and screening is not diagnostic.
03Transvaginal ultrasound
Why
Measure and characterise endometrium and assess uterine and adnexal structures.
Interpretation and limitations
Report complete visualisation, uniformity and focal lesions. Use the applicable ordinary or HRT threshold; incomplete or irregular views are not reassuring.
04Endometrial Pipelle biopsy
Why
Obtain histology for diffuse hyperplasia or malignancy when thickness or risk requires tissue.
Interpretation and limitations
An adequate benign result lowers risk but can miss focal disease. Insufficient tissue and recurrent bleeding require further cavity assessment.
05Outpatient hysteroscopy with targeted biopsy
Differential diagnosis
01
Vaginal or vulval disease
Atrophy, lichen sclerosus, trauma, infection and vulval malignancy can produce blood that appears to come from the uterus.
02
Cervical disease
Polyps, cervicitis and cervical cancer cause contact or spontaneous bleeding and require direct visual and diagnostic assessment.
03
Urinary tract bleeding
Infection, stone and urothelial malignancy can present as blood on underwear; urinalysis and source history generate a parallel urological pathway.
04
Rectal bleeding
Haemorrhoids, inflammatory disease and colorectal cancer can be mislocalised, particularly when blood is first seen during toileting.
Management
01First episodeRefer, examine and triage the endometriumFirst stepAny unexplained genital bleeding occurs after established menopause.+
1Apply NICE suspected-cancer referral criteria immediately, document HRT, tamoxifen, anticoagulants, risk and whether urinary or rectal bleeding is possible.
2Perform consented vulval, speculum and pelvic examination and arrange transvaginal ultrasound within the urgent local pathway.
3Use thickness, uniformity, focal findings and visualisation quality to determine biopsy, hysteroscopy or carefully safety-netted discharge.
02Endometrium above thresholdObtain tissue and inspect focal diseaseThe lining is over the applicable threshold, irregular, focally abnormal or not fully seen.+
1Arrange endometrial sampling through the urgent service, choosing hysteroscopy when a focal lesion, tamoxifen exposure or cavity discordance is present.
Complications
01
Delayed endometrial cancer
Attributing bleeding to age, HRT or anticoagulation can postpone histology and permit progression before oncological treatment.
02
Anaemia and recurrent haemorrhage
Repeated or heavy bleeding can deplete iron, cause symptomatic anaemia and occasionally require acute transfusion or haemostasis.
03
Invasive diagnostic burden
Poorly selected repeat biopsy and examination can cause pain, perforation, infection and distress without resolving a focal cavity lesion.
04
Unmanaged atrophy
Persistent dryness and tissue fragility can cause recurrent bleeding, urinary symptoms, dyspareunia and avoidance even after malignancy is excluded.
Monitoring and follow-up
Track referral, ultrasound, hysteroscopy and every histology result to a named clinician, including inadequate views and insufficient samples.
Record any further spotting, blood-stained discharge or bleeding after an initial benign assessment and re-refer rather than offering indefinite reassurance.
For HRT changes, document the exact preparation, progestogen schedule, adherence, adjustment date and agreed review interval under BMS guidance.
After atrophy treatment review symptoms and any recurrence; improvement does not retrospectively prove that the original bleeding was benign.
Escalate heavy loss, anaemia, pain, fever, mass symptoms or delayed cancer-pathway access through the responsible urgent service.
Special situations
One spot is enough
Endometrial cancer can present with a small first episode, so urgency depends on postmenopausal status rather than volume or recurrence.
Thin means low probability
A 4 mm or smaller fully visualised lining is a triage result, not permanent exclusion, and recurrent bleeding changes the post-test risk.
Uniformity matters with thickness
A focal lesion or unvisualised segment cannot be made reassuring by averaging it with a thin area of endometrium.
HRT schedule changes numbers
Sequential progestogen permits a thicker cyclical lining than continuous combined therapy, so their BMS reassurance thresholds differ.
Tamoxifen breaks simple measurement
Cystic and polypoid change makes endometrial thickness less discriminating, increasing the value of direct hysteroscopic assessment for symptoms.
Common pitfalls
01
Waiting for a second episode or anaemia before referring unexplained postmenopausal bleeding.
02
Assuming anticoagulation or vaginal atrophy removes the need to exclude endometrial and cervical cancer.
03
Applying a measured thin segment when the whole endometrium was not visible or was focally irregular.
04
Using the 7 mm sequential-HRT threshold for a patient on continuous combined HRT.
05
Treating an insufficient Pipelle sample as benign despite persistent bleeding or a focal ultrasound lesion.
06
Discharging recurrent PMB because the first ultrasound showed 4 mm or less without arranging hysteroscopy.
Practice
Two practice questions
Your practice draft is saved in this browser.
Question 1 of 2
0 correct
Obstetrics and gynaecologyOriginal SBA
Urgent referral threshold
A 58-year-old has one small episode of unexplained vaginal spotting 18 months after the final menstrual period. Examination is not yet performed and she is otherwise well. What is the correct initial pathway?
Sources and review status5 sources · checked 27 Aug 2026 · clinical review pending+
Sources
Sources and review status
National guidance is shown before implementation-dependent detail. Apply principles in context and verify current guidance when a decision affects care. Source check completed 27 Aug 2026; clinical approval remains outstanding.
Examination localises other sources. Inspect vulva for lesions and dermatoses and use a consented speculum examination to assess atrophic mucosa, trauma, discharge, cervical polyp and suspicious cervix. A bimanual examination may identify uterine or adnexal mass. Cervical screening is not a diagnostic test for symptomatic bleeding. If urine or rectal bleeding is plausible, investigate that system while maintaining the uterine pathway until the source is secure.
Transvaginal ultrasound measures the maximum anterior-posterior double-layer endometrium in the sagittal plane and assesses uniformity, focal lesions, fluid, uterus and adnexa. A clear uniform lining of 4 mm or less is used by many UK PMB pathways to identify a low probability of endometrial cancer after a first episode. Thickness above 4 mm, inability to visualise the whole endometrium, irregularity or a focal lesion prompts tissue and cavity assessment. A single thin measurement does not overrule recurrent bleeding.
Histology establishes hyperplasia and cancer. An outpatient Pipelle biopsy samples the endometrium without direct visualisation and is useful for diffuse disease, but focal polyps and localised lesions may be missed. Hysteroscopy directly inspects the cavity and allows targeted biopsy or polypectomy. Insufficient tissue is not automatically negative; interpret it with endometrial thickness, image quality, recurrence and risk. Persistent or recurrent PMB after benign assessment generally requires hysteroscopy or specialist re-evaluation.
HRT bleeding needs regimen-specific timing. Continuous combined HRT aims for amenorrhoea after adjustment, while sequential HRT produces expected cyclical withdrawal bleeding. The BMS joint guideline allows low-risk regimen adjustment for some bleeding within six months of starting or within three months of changing HRT. It advises urgent transvaginal ultrasound within six weeks when first bleeding occurs later than those intervals, or at any time when bleeding is heavy, prolonged or accompanied by relevant cancer risk.
Endometrial thresholds differ on HRT because progestogen schedule changes the lining. When the entire endometrium is uniform, BMS regards 4 mm or less on continuous combined HRT and 7 mm or less on sequential HRT as reassuring enough for regimen adjustment and safety-netting in low-risk patients. Greater thickness, focal abnormality, incomplete visualisation or persistent bleeding triggers urgent endometrial assessment. Do not apply the 7 mm sequential threshold to continuous combined HRT or to a non-HRT symptomatic patient.
Tamoxifen stimulates heterogeneous cystic endometrial change and polyps, reducing the value of a simple thickness threshold. PMB on tamoxifen generally needs specialist direct cavity and histological assessment. Other causes include vaginal or endometrial atrophy, polyps, hyperplasia, endometrial cancer, cervical cancer, vulval disease, infection and trauma. Ovarian oestrogen-producing tumours are uncommon but considered with a mass or unexpected endometrial proliferation.
Management follows diagnosis. Offer vaginal moisturisers, lubricants or local oestrogen for symptomatic genitourinary atrophy after appropriate assessment, with breast-cancer and hormone context considered. Remove symptomatic polyps and manage hyperplasia according to histology and fertility or surgical context. Endometrial cancer is referred to the gynaecological oncology team for staging and treatment. Every benign discharge plan must specify that recurrent spotting, blood-stained discharge or bleeding should return promptly.
Key points
Postmenopausal bleeding means vaginal bleeding after at least 12 months of spontaneous amenorrhoea from menopause; ask about HRT, tamoxifen, anticoagulants and whether blood may be urinary or rectal.
Refer unexplained PMB through the urgent suspected-cancer pathway at age 55 or older under NICE and consider the same pathway in younger patients.
Examine vulva, vagina and cervix with consent and a chaperone to identify atrophy, trauma, polyp or visible malignancy, but continue endometrial assessment even when atrophy seems likely.
Transvaginal ultrasound is the usual initial endometrial triage test; report whether the whole double-layer endometrium is seen, its maximum thickness, uniformity and any focal lesion or fluid.
A fully visualised uniform endometrium of 4 mm or less commonly defines low endometrial-cancer probability in non-HRT PMB pathways, but recurrence still requires further assessment.
An endometrium above 4 mm, irregular, focally abnormal or inadequately visualised generally leads to endometrial sampling and often hysteroscopy under the local urgent pathway.
For unscheduled bleeding on HRT, British Menopause Society guidance uses reassuring thresholds of 4 mm or less on continuous combined HRT and 7 mm or less on sequential HRT when the lining is uniform and fully seen.
A pelvic mass, offensive or blood-stained discharge, weight loss, anaemia, suspicious cervix or vulval lesion increases urgency and may indicate disease outside the endometrium.
Persistent or recurrent bleeding requires renewed cavity assessment even after a fully visualised thin endometrium or benign initial biopsy.
Tamoxifen can produce polyps and cystic endometrial change; ultrasound thickness is less reliable and symptomatic patients often need direct cavity assessment.
An endometrium that is irregular, focally abnormal or not completely visualised cannot be called reassuring by using the measurable thin segment.
Why
Directly inspect and sample focal polyps, irregular endometrium or persistent unexplained bleeding.
Interpretation and limitations
This resolves ultrasound-biopsy discordance and permits polyp removal. Complete visualisation and histology both need documented ownership.
06Full blood count and source-specific tests
Why
Assess anaemia and investigate urinary, rectal, cervical or infection alternatives when suggested.
Interpretation and limitations
Normal blood count does not remove cancer risk. Haematuria or rectal findings generate parallel pathways rather than premature closure of genital assessment.
2
Track specimen adequacy and histology to benign, hyperplasia or cancer management and repeat assessment when tissue is insufficient.
3EscalationEscalate heavy bleeding, pain, anaemia or mass symptoms while awaiting results rather than treating risk as a routine queue.
03HRT bleedingUse regimen timing and the correct thresholdBleeding occurs while using continuous combined or sequential hormone replacement therapy.+
1Confirm preparation, progestogen dose and adherence, start or change dates, expected withdrawal pattern and endometrial risk factors.
2Arrange urgent ultrasound for late-onset, heavy, prolonged or risk-bearing bleeding and apply 4 mm continuous or 7 mm sequential thresholds only to a fully visualised uniform lining.
3Adjust HRT and review when low risk and appropriate, but refer persistent, recurrent or above-threshold bleeding for endometrial assessment.
04Persistent or recurrentDo not let one thin scan close the caseBleeding returns or continues after a reassuring ultrasound or benign initial sample.+
1Reconfirm source, examination, HRT and tamoxifen context and review whether the original endometrium was fully visualised and tissue adequate.
2Refer for hysteroscopy and targeted biopsy or specialist re-evaluation to identify focal lesions and resolve discordant tests.
3Maintain urgent access and cancer-pathway ownership until symptoms and findings are reconciled in a documented final plan.
BMS advises urgent transvaginal ultrasound when bleeding first presents more than six months after starting HRT or more than three months after changing it, or sooner for heavy bleeding or risk factors.
Pipelle sampling can detect global endometrial disease but may miss a focal polyp; persistent symptoms, focal ultrasound findings or insufficient tissue requires hysteroscopy-directed assessment.
Treat vaginal atrophy or adjust HRT only after appropriate cancer exclusion, and give explicit instructions to return for any recurrent blood, spotting or discharge.